Trials / Withdrawn
WithdrawnNCT00598104
Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Novartis · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Not accepted
Summary
This study will evaluate the safety and efficacy of QAX576 against asthma attacks in adults with moderate persistent allergic asthma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | QAX576 | |
| DRUG | Placebo |
Timeline
- Start date
- 2008-01-01
- Primary completion
- 2008-12-01
- First posted
- 2008-01-18
- Last updated
- 2016-03-04
Source: ClinicalTrials.gov record NCT00598104. Inclusion in this directory is not an endorsement.